Suppr超能文献

神经生长因子作为眼部治疗药物:应用、挑战与未来方向。

Nerve Growth Factor as an Ocular Therapy: Applications, Challenges, and Future Directions.

机构信息

1. Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA.

出版信息

Semin Ophthalmol. 2021 May 19;36(4):224-231. doi: 10.1080/08820538.2021.1890793. Epub 2021 Feb 27.

Abstract

Nerve growth factor (NGF), the prototypical neurotrophin first discovered in the 1950s, has recently garnered increased interest as a therapeutic agent promoting neuronal health and regeneration. After gaining orphan drug status within the last decade, NGF-related research and drug development has accelerated. The purpose of this article is to review the preclinical and clinical evidence of NGF in various applications, including central and peripheral nervous system, skin, and ophthalmic disorders. We focus on the ophthalmic applications including not only the FDA-approved indication of neurotrophic keratitis but also retinal disease and glaucoma. NGF represents a promising therapy whose therapeutic profile is evolving. The challenges related to this therapy are reviewed, along with possible solutions and future directions.

摘要

神经生长因子(NGF)是 20 世纪 50 年代首次发现的典型神经营养因子,最近作为一种促进神经元健康和再生的治疗药物引起了更多关注。在过去十年获得孤儿药地位后,NGF 相关的研究和药物开发加速。本文的目的是综述 NGF 在各种应用中的临床前和临床证据,包括中枢和周围神经系统、皮肤和眼科疾病。我们重点介绍眼科应用,不仅包括 FDA 批准的神经营养性角膜炎适应症,还包括视网膜疾病和青光眼。NGF 代表一种有前途的治疗方法,其治疗谱正在不断发展。本文还综述了与这种治疗相关的挑战,以及可能的解决方案和未来方向。

相似文献

1
Nerve Growth Factor as an Ocular Therapy: Applications, Challenges, and Future Directions.
Semin Ophthalmol. 2021 May 19;36(4):224-231. doi: 10.1080/08820538.2021.1890793. Epub 2021 Feb 27.
2
Nerve growth factor therapy for corneal disease.
Curr Opin Ophthalmol. 2012 Jul;23(4):296-302. doi: 10.1097/ICU.0b013e3283543b61.
3
Nerve growth factor eye drops to treat glaucoma.
Drug News Perspect. 2010 Jul-Aug;23(6):361-7. doi: 10.1358/dnp.2010.23.6.1472299.
4
Can Nerve Growth Factor (NGF) Be a Treatment Option for Pediatric Eye Diseases?
Semin Ophthalmol. 2023 Jul;38(5):427-432. doi: 10.1080/08820538.2023.2168485. Epub 2023 Jan 22.
5
Topical treatment with nerve growth factor for neurotrophic keratitis.
Ophthalmology. 2000 Jul;107(7):1347-51; discussion 1351-2. doi: 10.1016/s0161-6420(00)00163-9.
6
The History of Nerve Growth Factor: From Molecule to Drug.
Biomolecules. 2024 May 29;14(6):635. doi: 10.3390/biom14060635.
7
Progress on the application of growth factor-related drugs in ophthalmology.
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2022 Nov 25;51(5):626-633. doi: 10.3724/zdxbyxb-2022-0075.
8
The nerve growth factor signaling and its potential as therapeutic target for glaucoma.
Biomed Res Int. 2014;2014:759473. doi: 10.1155/2014/759473. Epub 2014 Aug 31.
9
Nerve Growth Factor: Early Studies and Recent Clinical Trials.
Curr Neuropharmacol. 2018;16(10):1455-1465. doi: 10.2174/1570159X16666180412092859.
10
Neurotrophic keratopathy: Pros and cons of current treatments.
Ocul Surf. 2019 Oct;17(4):619-623. doi: 10.1016/j.jtos.2019.09.002. Epub 2019 Sep 14.

引用本文的文献

1
Human nerve growth factor delivery to the retina: Quantitative methodology and mathematical modeling in preclinical settings.
PNAS Nexus. 2025 Aug 11;4(8):pgaf250. doi: 10.1093/pnasnexus/pgaf250. eCollection 2025 Aug.
5
Current and Emerging Therapeutic Strategies for the Management of Neurotrophic Keratitis.
Drugs. 2025 Mar;85(3):283-291. doi: 10.1007/s40265-025-02147-3. Epub 2025 Jan 23.
6
The History of Nerve Growth Factor: From Molecule to Drug.
Biomolecules. 2024 May 29;14(6):635. doi: 10.3390/biom14060635.
8
An Update on Strategies to Deliver Protein and Peptide Drugs to the Eye.
ACS Omega. 2023 Sep 22;8(39):35470-35498. doi: 10.1021/acsomega.3c02897. eCollection 2023 Oct 3.
9
Polarized RPE Secretome Preserves Photoreceptors in Retinal Dystrophic RCS Rats.
Cells. 2023 Jun 22;12(13):1689. doi: 10.3390/cells12131689.

本文引用的文献

2
Ocular Drug Delivery: Present Innovations and Future Challenges.
J Pharmacol Exp Ther. 2019 Sep;370(3):602-624. doi: 10.1124/jpet.119.256933. Epub 2019 May 9.
3
Effect of recombinant human nerve growth factor eye drops in patients with dry eye: a phase IIa, open label, multiple-dose study.
Br J Ophthalmol. 2020 Jan;104(1):127-135. doi: 10.1136/bjophthalmol-2018-312470. Epub 2019 Apr 3.
4
Innovative Therapy for Alzheimer's Disease-With Focus on Biodelivery of NGF.
Front Neurosci. 2019 Feb 5;13:38. doi: 10.3389/fnins.2019.00038. eCollection 2019.
5
The Effect of Aging on Nerve Morphology and Substance P Expression in Mouse and Human Corneas.
Invest Ophthalmol Vis Sci. 2018 Nov 1;59(13):5329-5335. doi: 10.1167/iovs.18-24707.
6
Phase I Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis.
Ophthalmology. 2018 Sep;125(9):1468-1471. doi: 10.1016/j.ophtha.2018.03.004. Epub 2018 Apr 10.
7
Phase II Randomized, Double-Masked, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis.
Ophthalmology. 2018 Sep;125(9):1332-1343. doi: 10.1016/j.ophtha.2018.02.022. Epub 2018 Apr 10.
8
Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis.
J Anaesthesiol Clin Pharmacol. 2018 Jan-Mar;34(1):111-116. doi: 10.4103/joacp.JOACP_389_15.
10
Nanotechnological strategies for nerve growth factor delivery: Therapeutic implications in Alzheimer's disease.
Pharmacol Res. 2017 Jun;120:68-87. doi: 10.1016/j.phrs.2017.03.020. Epub 2017 Mar 27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验